AptarGroup (ATR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
12 May, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who announced his planned retirement after nearly 10 years in the role.
The meeting was held virtually to increase accessibility for all stockholders.
The agenda and meeting rules were made available online, and the meeting was conducted per bylaws.
Board and executive committee updates
Gael Touya, with over 30 years at the company, will become President and CEO on September 1, 2026, with the current CEO remaining as advisor through year-end.
The board expects to appoint Gael Touya as a director on September 1, 2026.
Key executives and independent accountants were introduced and present for the meeting.
Overview of voting outcomes
A quorum was confirmed, and polls were open for voting on all agenda items.
Four directors were elected to serve until the 2029 annual meeting.
Advisory approval of executive compensation and ratification of the independent accounting firm for 2026 both passed by majority vote.
Latest events from AptarGroup
- Pharma leads growth with strong pipeline, digital health expansion, and disciplined capital allocation.ATR
Jefferies Global Healthcare Conference 20259 Jul 2026 - Profitable growth driven by pharma innovation, cost discipline, and strong shareholder returns.ATR
Investor Day 20259 Jul 2026 - Pharma leads growth as financial targets are met and supply chain resilience supports global operations.ATR
45th Annual William Blair Growth Stock Conference9 Jul 2026 - Double-digit earnings growth in 2024, led by pharma and closures, with strong 2025 outlook.ATR
Q4 20248 Jul 2026 - Q1 2025 saw resilient margins and Pharma growth despite lower sales and higher tax rates.ATR
Q1 20258 Jul 2026 - 2025 growth led by pharma and innovation, with strong margins and resilient consumer segments.ATR
Bank of America 2026 Global Agriculture and Materials Conference8 Jul 2026 - Pharma-led growth, innovation in drug delivery, and increased buybacks drive strong outlook.ATR
Jefferies London Healthcare Conference 20258 Jul 2026 - Pharma innovation, operational recovery, and sustainability drive strong 2025 performance.ATR
16th Annual Wells Fargo Industrials & Materials Conference9 Jun 2026 - Pharma-led growth, innovation in drug delivery, and strong financials drive long-term value.ATR
Jefferies Global Healthcare Conference 20269 Jun 2026